Additional Information Index Accounting policies 77, 142, 200 Information Technology 60 Acerta Pharma 26, 29, 62-74, 173 Intangible assets 73, 80, 101, 134-135, 143, 157-159 Acquisitions 173-177 Intellectual Property 57 Affordable Care Act 13, 49, 82 Interest-bearing loans and borrowings 162-163 Almirall 68, 72, 176 Key performance indicators 16-19 Animal research 48 Leases 144, 146, 191 Annual General Meeting 97, 105, 237 Life-cycle of a medicine 8-9 Articles of Association 237 Litigation 20, 80, 101, 135, 145, 185-200 AstraZeneca at a glance 2-3 Lynparza 26-29 Audit Committee 84, 98-102 Manufacturing and Supply 58-59 Audit Committee Report 98-102 Market denitions 239 Bioethics 47-48 Marketplace 11-15 Biologics 12, 15 Modern Slavery Act 56 BMS 63-69, 175 Oncology 25-29 Board of Directors 86-87 Operating profit 1, 62-65, 148-149 Brilinta Brilique 31-33 Operational overview 2-3 Business model 8-10 Other Disease Areas 38-41 Cambridge 7 Other investments 144, 160 Capitalisation and shareholder return 76 PARTHENON programme 33 Cardiovascular and Metabolic diseases 30-34 Patent Expiries 15, 211-213 Cash and cash equivalents 162 Patents See Intellectual Property Chairmans Statement 82-83 Patient safety 47-48 Chief Executive Ofcers Review 4-6 Personalised healthcare 46 Clinical trials 8-9, 46-48 Physician Payments Sunshine Act 52 Code of Conduct 52, 95-96 Political donations 97 Commitments and contingent liabilities 185-191 Post-retirement benets 80, 136, 165-171 Community investment 53 Product revenue information 226-230 Company history 237 Property, plant and equipment 73 Compliance and Internal Audit Services 95 Provisions 165 Consolidated Statements 138-141 Regulatory requirements 13-14 Corporate Governance 82-131 Related party transactions 192, 234 Corporate Information 237 Relations with shareholders 93 Corporate Integrity Agreement 98 Remuneration 103-121 Deniens 176-177 Remuneration Policy 122-132 Development pipeline 23, 204-210 Research and Development 45-48 Diabetes 32-34 Reserves 172 Directors interest in shares 114-115 Respiratory 37 Directors responsibility statement 133 Restructuring 43, 69, 148 Diversity 55-56, 90-91 Results of operations 2016 65 Dividends 3, 76, 96, 172 Risk 20-22, 214-225 Earnings per Ordinary Share 152 Sales and Marketing 48-51 Employee costs and share plans for employees 182-184 Sales by geographical area 226-230 Employees 52-57 Sales by therapy area 23, 226-230 Environmental impact 60-61 Sarbanes-Oxley Act 81 Ethics 52, 95 Science Committee 93-94 Segment information 152-153 Externalisation 23-24, 67 Finance income and expense 149 Senior management SET 85, 88-89 Financial instruments 149 Share capital 172 Financial position 2016 72 Share repurchase 76, 172 Financial Review 62-81 Shareholder distributions 3, 76, 96 Shareholder information 232-236 Financial risk management 76-77, 177-181 Strategic priorities 2, 5, 16-19 Financial Statements 2016 133-192 Sustainability: supplementary information 231 Financial summary 1 Tagrisso 4-5, 26-29 Gender diversity 55-56 Takeda 24, 36-37, 57 Geographical Review 226-230 Taxation 69, 76, 81, 143, 150-152, 200 Global pharmaceutical sales 11-12 Glossary 239-241 Taxation information for shareholders 234-236 Group Financial Record 203 Therapy Area Overview and Pipeline 23-41 Group Subsidiaries and Holdings 193-196 Trade and other payables 72, 144, 164 Trade and other receivables 72, 144, 162, 181 Growth Platforms 17 Trade marks 238 Healthy Heart Africa programme 49 Values and Purpose 8 Human Rights 56-67 Young Health Programme 53 Independent auditors report 134-137 ZS Pharma 34, 62-73, 174-175 Infection, Neuroscience and Gastrointestinal See Other Disease Areas 242 AstraZeneca Annual Report and Form 20-F Information 2016 Additional Information Important information for readers of this Annual Report Cautionary statement regarding Inclusion of Reported performance, AstraZeneca websites forward-looking statements &RUH QDQFLDO PHDVXUHV DQG FRQVWDQW Information on or accessible through our The purpose of this Annual Report is to exchange rate growth rates websites, including www.
com, provide information to the members of the AstraZenecas determination of non-GAAP www.
The Company and its Directors, measures together with our presentation of www.
com, does not form part employees, agents and advisers do not them within our financial information may of and is not incorporated into this Annual accept or assume responsibility to any other differ from similarly titled non-GAAP Report.
person to whom this Annual Report is measures of other companies.
shown or into whose hands it may come External third party websites and any such responsibility or liability is Statements of competitive position, Information on or accessible through any expressly disclaimed.
In order, among other growth rates and sales third party or external website does not form things, to utilise the safe harbour provisions In this Annual Report, except as otherwise part of and is not incorporated into this of the US Private Securities Litigation stated, market information regarding the Annual Report.
Reform Act of 1995 and the UK Companies position of our business or products relative Act 2006, we are providing the following to its or their competition is based upon Figures cautionary statement: This Annual Report published statistical sales data for the Figures in parentheses in tables and in the contains certain forward-looking statements 12 months ended 30 September 2016 Financial Statements are used to represent with respect to the operations, performance obtained from IMS Health, a leading supplier negative numbers.
and financial condition of the Group, of statistical data to the pharmaceutical including, among other things, statements industry.
Unless otherwise noted, for the about expected revenues, margins, US, dispensed new or total prescription earnings per share or other financial or other data and audited sales data are taken, measures.
Forward-looking statements are respectively, from IMS Health National statements relating to the future which are Prescription Audit and IMS National Sales based on information available at the time Perspectives for the 12 months ended such statements are made, including 31 December 2016: such data is not information relating to risks and uncertainties.
adjusted for Medicaid and similar rebates.
Although we believe that the forwardExcept as otherwise stated, these market looking statements in this Annual Report share and industry data from IMS Health are based on reasonable assumptions, the have been derived by comparing our sales matters discussed in the forward-looking revenue with competitors and total market statements may be inuenced by factors sales revenues for that period, and except that could cause actual outcomes and as otherwise stated, growth rates are given results to be materially different from those at CER.
For the purposes of this Annual expressed or implied by these statements.
Report, unless otherwise stated, references The forward-looking statements reect to the world pharmaceutical market or knowledge and information available at the similar phrases are to the 54 countries date of the preparation of this Annual Report contained in the IMS Health database, and the Company undertakes no obligation which amounted to approximately 96% to update these forward-looking statements.
in value of the countries audited by We identify the forward-looking statements IMS Health.
by using the words anticipates, believes, expects, intends and similar expressions in such statements.
Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things, those factors identied in the Risk section from page 214 of this Annual Report.
Nothing in this Annual Report should be construed as a profit forecast.
AstraZeneca Annual Report and Form 20-F Information 2016 243 Additional Information 5HJLVWHUHG RFH DQG FRUSRUDWH Registrar headquarters Equiniti Limited AstraZeneca PLC Aspect House 1 Francis Crick Avenue Spencer Road Cambridge Biomedical Campus Lancing Cambridge CB2 0AA West Sussex BN99 6DA UK UK Tel: 44 0 20 3749 5000 Tel: freephone in the UK 0800 389 1580 Tel: outside the UK 44 0 121 415 7033 Investor relations UK: as above Swedish Central Securities Depository Euroclear Sweden AB US: PO Box 191 Investor Relations SE-101 23 Stockholm AstraZeneca Pharmaceuticals LP Sweden One MedImmune Way Tel: 46 0 8 402 9000 Gaithersburg MD 20878 US US Depositary Tel: 1 301 398 0000 Citibank Shareholder Services PO Box 43077 Providence RI 02940-3077 US Tel: toll free in the US 1 888 697 8018 For more information please see Tel: outside the US 1 781 575 4555 www.
com 244 AstraZeneca Annual Report and Form 20-F Information 2016 This Annual Report is printed on Heaven 42 which is FSC Designed and produced by FHUWLHG YLUJLQ EUH 7KH SXOS LV D PL[ SDUWO EOHDFKHG XVLQJ an Elemental Chlorine Free process and partly bleached using a Totally Chlorine Free process.
It is printed in the UK by Pureprint Board and SET photography using its and environmental printing by Marcus Lyon technology, and vegetable inks were used throughout.
Both the manufacturing mill and the printer are registered to the Environmental Management System ISO 14001 and are Forest Stewardship Council FKDLQ RI FXVWRG FHUWLHG AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK Tel: 44 0 20 3749 5000 This Annual Report is also available on our website, www.
